October 19th 2024
Offering certain radiotherapy modalities based on disease burden may play a role in the outcomes of those with ES-SCLC, according to James Ninia, MD.
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
18th Annual New York GU Cancers Congress™
March 28-29, 2025
Register Now!
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
Stereotactic Radiosurgery Safe and Effective for Brainstem Metastases
June 2nd 2021The results from a retrospective trial that found stereotactic radiosurgery produced comparable results for both brainstem metastases and nonbrainstem brain metastases suggest both groups of patients should be eligible for stereotactic radiosurgery clinical trials.
Sexual Dysfunction Not Well Addressed in Female Cancer Survivors
November 4th 2020“Sexual dysfunction is an unfortunately common side effect of cancer treatment, and there appears to be a large gender disparity in how physicians discuss sexual health with their patients,” said lead study author James Taylor, MD, MPH.
SBRT Appears to be Superior to CRT for Controlling Pain Related to Spinal Metastases
October 31st 2020Stereotactic body radiotherapy may be superior to conventional palliative radiotherapy in improving the complete response rate for pain related to spinal metastases at 3- and 6-months post-radiation.